Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 5:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 85,717 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 1 Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Bioavailability and Pharmacokinetics of Mango

NCT03365739
View directory record Official record
Conditions
Healthy Subjects
Interventions
Active Comparator 1, Active Comparator 2, Control Comparator
Dietary Supplement
Lead sponsor
Clinical Nutrition Research Center, Illinois Institute of Technology
Industry
Eligibility
20 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 14, 2020 · Synced Oct 25, 2026, 5:48 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma

NCT02059239
View directory record Official record
Conditions
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Interventions
Bendamustine, Carmustine, Etoposide, Melphalan, Cytarabine, Alemtuzumab, Autologous Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, Rituximab
Drug · Biological
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 25, 2026, 5:48 AM EDT
Completed Phase 2 Interventional

Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia

NCT01748877
View directory record Official record
Conditions
Post Herpetic Neuralgia
Interventions
NXN-462, Placebo
Drug
Lead sponsor
NeurAxon Inc.
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Oct 25, 2026, 5:48 AM EDT
Completed Not applicable Interventional Results available

Pain Rehabilitation Virtual Reality (PRVR): Innovations to Enhance Mobility in the Presence of Pain

NCT04636177
View directory record Official record
Conditions
Chronic Pain, Musculoskeletal Pain, Fibromyalgia, Virtual Reality
Interventions
Pain Rehabilitation Virtual Reality (PRVR), Standard Physiotherapy Rehabilitation (SPR)
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
10 Years to 17 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Menlo Park, California • Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 25, 2026, 5:48 AM EDT
Terminated Not applicable Interventional Results available

Safety and Effectiveness of Ozurdex Steroid Implants for DME After Vitrectomy Surgery

NCT01788475
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Dexamethasone
Drug
Lead sponsor
Lahey Clinic
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Peabody, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 25, 2026, 5:48 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Role of CYP2C19 Polymorphism in the Drug Interaction Between Clopidogrel and Omeprazole

NCT01094275
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Clopidogrel 75mg, Omeprazole 20mg
Drug
Lead sponsor
Neil Kleiman, MD
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Oct 25, 2026, 5:48 AM EDT
Completed Phase 1 Interventional Results available

AGN-Cogni.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients

NCT05375539
View directory record Official record
Conditions
Prostate Cancer
Interventions
AGN-Cogni.Q
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
40 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 25, 2026, 5:48 AM EDT
Completed Not applicable Interventional

Vestibular Innovation in Pain

NCT06559839
View directory record Official record
Conditions
Pain, Fatigue, Quality of Life
Interventions
Vestibulocortical Stimulation
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 99 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Oct 25, 2026, 5:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I, Open Label,Crossover Food-Effect and Absolute Bioavailability Study of WCK2349 and WCK771 in Healthy Adult Human Volunteers

NCT01875939
View directory record Official record
Conditions
Effect of Food
Interventions
Oral WCK2349, IV WCK771
Drug
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2013 · Synced Oct 25, 2026, 5:48 AM EDT
Completed Phase 1 Interventional

Viral Therapy in Treating Patients With Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Did Not Respond to Platinum Chemotherapy

NCT00602277
View directory record Official record
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Laboratory Biomarker Analysis, Wild-type Reovirus
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 8, 2016 · Synced Oct 25, 2026, 5:48 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

NCT02648477
View directory record Official record
Conditions
Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative, Progesterone Receptor Positive, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma
Interventions
Anastrozole, Doxorubicin Hydrochloride, Exemestane, Laboratory Biomarker Analysis, Letrozole, Pembrolizumab
Drug · Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
6
States / cities
Corona, California • Duarte, California • Lancaster, California + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2024 · Synced Oct 25, 2026, 5:48 AM EDT
Terminated Phase 2 Interventional

Safety and Tolerability of a Novel Malathion Formulation in Infants and Toddlers With Head Lice

NCT00291057
View directory record Official record
Conditions
Lice Infestations
Interventions
MALG
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
6 Months to 24 Months
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
5
States / cities
Scottsdale, Arizona • St. Petersburg, Florida • West Palm Beach, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2013 · Synced Oct 25, 2026, 5:48 AM EDT
Completed Not applicable Interventional

Rehabilitation Team Functioning and Patient Outcomes

NCT00237757
View directory record Official record
Conditions
Stroke
Interventions
Information feedback
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 3, 2013 · Synced Oct 25, 2026, 5:48 AM EDT
Terminated Phase 1 Interventional

Phase I Study of Temozolomide, Valproic Acid and Radiation Therapy in Patients With Brain Metastases

NCT00437957
View directory record Official record
Conditions
Brain Metastases
Interventions
Temozolomide, Valproic Acid, Whole Brain Radiation Therapy
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 25, 2026, 5:48 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

NCT05355701
View directory record Official record
Conditions
Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma, Advanced Colorectal Cancer (Part 1)
Interventions
PF-07799933, binimetinib, cetuximab, midazolam, fluorouracil, leucovorin, oxaliplatin
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
31
States / cities
Fayetteville, Arkansas • Rogers, Arkansas • Springdale, Arkansas + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 25, 2026, 5:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Carbavance™ (RPX2014/RPX7009) in Healthy Adult Subjects

NCT02073812
View directory record Official record
Conditions
Healthy Subjects
Interventions
RPX7009 and RPX2014
Drug
Lead sponsor
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Oct 25, 2026, 5:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Okla Achokma Project

NCT06633939
View directory record Official record
Conditions
Healthy, Diet, Physical Activity
Interventions
Behavioral Treatment
Behavioral
Lead sponsor
University of Southern Mississippi
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Hattiesburg, Mississippi
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Oct 25, 2026, 5:48 AM EDT
Completed Not applicable Interventional

Melatonin for Huntington's Disease (HD) Gene Carriers With HD Related Sleep Disturbance - a Pilot Study

NCT04421339
View directory record Official record
Conditions
Huntington Disease
Interventions
Melatonin, Placebo
Dietary Supplement · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 25, 2026, 5:48 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Understanding and Predicting Breast Cancer Events After Treatment

NCT02791581
View directory record Official record
Conditions
Breast Cancer
Interventions
Cardiac MRI
Diagnostic Test
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older · Female only
Enrollment
403 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2032
U.S. locations
66
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Tampa, Florida + 52 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 25, 2026, 5:48 AM EDT
Recruiting Not applicable Interventional

Causal Role of Delta-beta Coupling for Goal-directed Behavior in Anhedonic Depression

NCT06132581
View directory record Official record
Conditions
Major Depressive Disorder, Anhedonia
Interventions
Delta-beta tACS via the Neurocare Direct Current Stimulator Multi-Channel 4, Theta-gamma tACS via the Neurocare Direct Current Stimulator Multi-Channel 4, Sham tACS via the Neurocare Direct Current Stimulator Multi-Channel 4
Device
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 25, 2026, 5:48 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents

NCT03434119
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/Lixisenatide, Insulin glargine (HOE901), Background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
85
States / cities
Montgomery, Alabama • Little Rock, Arkansas • Anaheim, California + 63 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 25, 2026, 5:48 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About the Safety of BIIB142 and How it is Processed in the Body of Healthy Adult Participants Aged 18 to 55 Years Old

NCT07133828
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BIIB142, BIIB142-Matching Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 25, 2026, 5:48 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Outcomes of Opioid Addicted Prisoners With Extended-Release Injectable Naltrexone

NCT02617628
View directory record Official record
Conditions
Opiate Dependence
Interventions
extended release naltrexone
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 25, 2026, 5:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Levetiracetam 750 mg Tablets Under Fasting Conditions

NCT00826865
View directory record Official record
Conditions
Seizures
Interventions
Levetiracetam
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 25, 2026, 5:48 AM EDT